PERJETA (pertuzumab) Patient Assistance Program
Don’t let the high cost of brand specialty HER2-targeted therapy stand between you and the treatment you need. We help eligible patients access Perjeta (pertuzumab) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
- Clear & Transparent Pricing
- Paperwork & Doctor-Coordination
- Comprehensive Support: From Application to Entire Journey.
- Annual Re-certification And Refills Management
- Medicare Part D Patients Accepted
HIPAA Compliant
BBB Accredited
Secure Website
Key Takeaways:
- Perjeta (pertuzumab) is FDA-approved in combination with Herceptin (trastuzumab) and chemotherapy for HER2-positive metastatic breast cancer (first-line), neoadjuvant (before-surgery) treatment of HER2-positive locally advanced/inflammatory/early breast cancer, and adjuvant (after-surgery) treatment of HER2-positive early breast cancer at high risk of recurrence.
- Without assistance, Perjeta costs commonly run $5,500–$7,000 per IV infusion (every 3 weeks). Combined with Herceptin and chemotherapy, the regimen commonly costs $15,000+ per cycle.
- Through AffordMyPrescriptions, qualifying patients can access Perjeta coverage for a flat $69.95 per month — our advocacy team manages the entire enrollment, infusions, and renewal process.
- There is no biosimilar version of Perjeta available in the U.S. as of 2026. A combination subcutaneous formulation (Phesgo, fixed-dose Perjeta + Herceptin) is also available.
What Is Perjeta Prescription Assistance Program?
The Perjeta Prescription Assistance Program is a manufacturer-sponsored initiative that provides Perjeta infusions at little or no medication cost to qualifying patients based on income and insurance status. The program is designed for HER2+ breast cancer patients who are uninsured or underinsured, as well as Medicare beneficiaries.
Navigating the program on your own means dealing with eligibility verification, oncology-team coordination, HER2 testing documentation, prior-authorization, infusion scheduling, cardiac monitoring schedules, and renewal deadlines.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your enrollment, from initial application through ongoing infusion-schedule coordination and annual re-certification — so you focus on your treatment, not paperwork.
Pharmacy Price Comparison
- Without assistance, Perjeta infusions cost roughly $5,500–$7,000 each — and the full Perjeta + Herceptin + chemo regimen commonly exceeds $15,000 per cycle. A Patient Assistance Program is the meaningful path forward — if you qualify:
| Pharmacy(With Coupon) | PrIce (30-Day)* | You Save W/ Us |
|---|---|---|
| Per IV infusion (Perjeta) | ~$6,500.00 | Save ~$6,430/dose |
| Combined with Herceptin | ~$13,000+/cycle | Save thousands |
| Phesgo SC combo | ~$13,000/cycle | Save thousands |
| Annual cost (metastatic) | ~$140,000+ | Save ~$139,000+/yr |
| Adjuvant 1-year course | $140,000+ | Save ~$139,000+ total |
*Just a heads-up — retail prices are estimates based on public data and vary by pharmacy. AffordMyPrescriptions Advocacy Service bypasses this by using drug manufacturer programs to secure your medication directly at no cost or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Perjeta Prescription Program?
The Patient Assistance Program is free to apply for and provides Perjeta infusions at little or no medication cost if approved. But the process involves detailed applications, oncology-team coordination, HER2 testing documentation, infusion scheduling (typically given alongside Herceptin), cardiac monitoring, and ongoing renewal management. Our $69.95/month service covers full advocacy.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for medication assistance programs.
We Advocate
Our specialists help gather documentation, complete applications, and coordinate with program providers.
Receive Medication
Once approved, you may receive your medication through the assistance program while we help manage ongoing paperwork and renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Perjeta:
Limitations of Coupons
- Prices fluctuate — savings aren’t guaranteed month-to-month
- Copay accumulators may prevent savings from counting toward deductible
- Coupon cards expire and require constant renewal
Still $5,500–$7,000 per infusion per month even with the best discount
- Can’t be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
- Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
- Medication supplied directly through the assistance program
We manage all paperwork, refills, and annual renewals
- If denied, we explore alternative savings on your behalf
DO YOU QUALIFY?
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Perjeta assistance.
- You Are A U.S. Citizen Or Legal Resident
- You Have A Valid Perjeta Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured, Underinsured, Or A Medicare Part D Beneficiary
- You Have Recently Experienced A Change In Financial Circumstances That Affects Your Ability To Pay
Not sure if you qualify? Our pre-qualification check is completely free. If we can’t help, you won’t be charged.
Understanding Perjeta:
Perjeta (pertuzumab) is an intravenous (IV) HER2-targeted monoclonal antibody used in combination with Herceptin (trastuzumab) and chemotherapy to treat HER2-positive breast cancer. It is approved for first-line metastatic disease, neoadjuvant treatment of high-risk early breast cancer, and adjuvant treatment of high-risk early breast cancer.
How Perjeta Works:
Perjeta is a monoclonal antibody that targets HER2-positive breast cancers by binding to a specific region of the HER2 receptor. Unlike other treatments, it blocks HER2 from pairing with other family members, such as HER3, which is a vital step for cancer cell growth. When used with Herceptin, it creates a “dual HER2 blockade” that provides a more powerful and comprehensive interruption of cancer signaling than using a single antibody alone.
Form and use:
This medication is administered as an intravenous (IV) infusion every three weeks, typically alongside Herceptin and chemotherapy. Treatment begins with a higher loading dose followed by regular maintenance doses given over 30 to 60 minutes. For increased convenience, a fixed-dose subcutaneous injection called Phesgo is also available, which combines both Perjeta and Herceptin into a single administration.
Generic availability:
As of 2026, there are no FDA-approved biosimilar versions of Perjeta or the combination product Phesgo available in the United States. While several biosimilars exist for Herceptin, Perjeta remains available only as a brand-name medication. Patients may choose between the individual IV infusions or the combined subcutaneous injection based on convenience and their oncology team’s recommendation.
Warnings:
Perjeta carries serious boxed warnings for embryo-fetal toxicity and the potential for heart muscle weakening (left-ventricular dysfunction). Because of these risks, cardiac function must be monitored regularly via echocardiograms or MUGA scans throughout the treatment period. Patients should also be aware of potential infusion reactions and must immediately report symptoms like chest pain, swelling, or new shortness of breath.
FAQ (Frequently Asked Questions)
How Much Does Perjeta Cost Without Insurance?
Per-infusion costs commonly run $5,500–$7,000 for Perjeta alone. Combined with Herceptin and chemotherapy, the regimen commonly costs $15,000+ per cycle. Annual treatment costs commonly reach $140,000+. Through AffordMyPrescriptions, qualifying patients receive Perjeta at no medication cost — our $69.95 monthly fee covers full advocacy and program management.
How Is Perjeta Different From Herceptin?
Both target HER2, but they bind different parts of the HER2 receptor. Herceptin binds the extracellular domain IV; Perjeta binds domain II and blocks HER2 from pairing with HER3 (a key signaling step). The two antibodies have complementary mechanisms — that’s why they are typically used together as ‘dual HER2 blockade’ for first-line metastatic disease and high-risk early breast cancer.
What Is Phesgo, And How Is It Different From Perjeta?
Phesgo is a fixed-dose subcutaneous combination of Perjeta + Herceptin in a single injection (with hyaluronidase to enable subcutaneous administration). It delivers the same medicines as separate IV Perjeta + Herceptin infusions, but in a much shorter administration time (5–8 minutes for SC vs. 90+ minutes for two IV infusions). Whether Phesgo or separate IV infusions is right depends on logistics and your treatment plan.
Why Is Cardiac Monitoring Required?
Both Perjeta and Herceptin can cause cardiomyopathy (weakening of the heart muscle). Cardiac function (LVEF) is assessed at baseline and at regular intervals during therapy with echocardiogram or MUGA scan. Most cases are reversible if caught early and treatment is paused or stopped.
Can I Get Perjeta Through The PAP If I Have Medicare?
Yes. Medicare beneficiaries can typically qualify for Perjeta Patient Assistance, especially if you face significant out-of-pocket costs under medical or pharmacy benefits. The manufacturer’s commercial copay assistance program is reserved for commercially insured patients only.
What If My Application Is Denied?
If your initial application is denied, we explore alternatives — the manufacturer’s copay assistance program if you have commercial insurance, independent foundations such as the PAN Foundation, HealthWell Foundation, Susan G. Komen, or Living Beyond Breast Cancer, or asking your oncology team whether the Phesgo SC combo or a different HER2-targeted regimen would be appropriate. If we cannot find a path, you will not be charged our service fee.
Take Control of Your Medication Costs
If you are struggling with the high cost of Perjeta, our team may be able to help you access assistance programs designed to make brand specialty HER2-targeted therapy affordable. Check your eligibility today.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.